Please login to the form below

Not currently logged in
Email:
Password:

Astellas appoints Dr Songlin Xue head of global pharmacovigilance

He joins from Takeda and was formerly at Novartis and Wyeth

Dr Songlin Xue has moved to Astellas Pharma to take up the US-based role of head of global pharmacovigilance (PV).

He will work out of the Japanese pharma company's Northbrook, Illinois headquarters for the Americas and report to Astellas chief medical officer Sef Kurstjens.

Dr Xue has spent more than 20 years in the pharmaceutical industry, most recently at Takeda, where he was senior vice president, head global pharmacovigilance.

Prior to joining Takeda, Dr Xue held posts with a number of global pharmaceutical companies, including Novartis and Wyeth. 

Astellas president and CEO Yoshihiko Hatanaka said: “I am pleased that Dr Xue will be joining us at Astellas as head of global pharmacovigilance. Dr Xue's knowledge and experience will help the company pursue its operational excellence and further enhance our global PV and product compliance capabilities.”

16th April 2013

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics